Related Experiment Video

Updated: Jun 11, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls

J E Bohonowych1, U Gopal, J S Isaacs

  • 1Department of Cell & Molecular Pharmacology, Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA.

Journal of Oncology
|July 15, 2010
PubMed

Insights

Targeting heat shock protein 90 (Hsp90) may overcome resistance to anti-angiogenic therapies by inhibiting multiple tumor growth pathways. This approach shows promise for more effective and durable tumor repression compared to single-target treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tumor vascularization is critical for tumor growth, progression, and treatment response.
  • Anti-angiogenic therapies face challenges due to intrinsic and acquired tumor resistance.
  • Heat shock protein 90 (Hsp90) inhibition offers a strategy to target multiple signaling pathways involved in tumor resiliency.

Purpose of the Study:

  • To review Hsp90's role in regulating angiogenesis and tumor growth.
  • To discuss the challenges posed by redundant signaling pathways in anti-angiogenic therapy.
  • To explore Hsp90-targeted strategies for overcoming treatment resistance.

Main Methods:

  • Review of literature on Hsp90, angiogenesis, and cancer therapy.
  • Analysis of Hsp90's regulation of key angiogenic factors and signaling pathways.
  • Discussion of clinical challenges and therapeutic strategies.

Main Results:

  • Hsp90 modulates both HIF/VEGF-dependent and independent angiogenesis.
  • Hsp90 targets receptor tyrosine kinases, influencing drug resistance.
  • Tumor microenvironment factors complicate anti-angiogenic and Hsp90-targeted therapies.

Conclusions:

  • Hsp90 inhibition presents a promising strategy to overcome resistance to anti-angiogenic therapies.
  • Targeting Hsp90 may lead to more robust and enduring tumor repression.
  • Addressing clinical challenges, including tumor microenvironment, is crucial for effective Hsp90-targeted strategies.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...